Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development

被引:26
作者
Phillips, AN [1 ]
Youle, M [1 ]
Johnson, M [1 ]
Loveday, C [1 ]
机构
[1] UCL, Royal Free & Univ Coll, Sch Med,Royal Free Ctr HIV Med, Dept Primary Care & Populat Sci, Royal Free Campus,Rowland Hill St, London NW3 2PF, England
关键词
HIV; antiretroviral therapy; combination; stochastic model; resistance mutation;
D O I
10.1097/00002030-200111230-00001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To use a stochastic model to gain insights into the consequence for resistance development of different drug use patterns. Methods: We consider use of three drugs (A, B and C) where for each drug one and only one viral mutation is associated with ability to replicate (effective reproductive ratio, R > 1) in the presence of that drug as monotherapy. For drug A mutation is a, etc. We define eight populations of short-lived infected cells that live 1 day: Vo with no mutations a, b, c; Va with mutation a only, Vab with mutations a and b, etc. A random number generator was used to determine whether mutations occur in any one round of replication and to sample from a Poisson distribution to determine for each cell the number of cells of the same population created in the next generation, using the R operative at that time. Values of R depended on drug exposure, cost of resistance and availability of target cells. Results: Treatment strategies and the resulting percentage (over 100 runs) developing full 'resistance' in 1500 days (Vabc not equal 0) were: (i) ABC 1500 days 0%; (6) A 300 days, AB 300 days, ABC 900 days 100%; (iii) AB 300 days, ABC 1200 days 33%; (iv) ABC 2/ 3 1500 days 15%; (v) ABC 1/2 1500 days 100%; (vi) ABC 50 days, no drugs 50 days, for 1500 days 1%, where ABC 2/3 means on-drug for 2 days in every 3, ABC 1/2 represents on-drug for 1 day in every 2, and represents suboptimal adherence. Conclusions: This model helps to develop understanding of key principles concerning development of resistance under different patterns of treatment use. (C) 2001 Lippincott Williams Wilkins.
引用
收藏
页码:2211 / 2220
页数:10
相关论文
共 41 条
[1]  
ANDERSON R M, 1991
[2]   Virus dynamics and drug therapy [J].
Bonhoeffer, S ;
May, RM ;
Shaw, GM ;
Nowak, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (13) :6971-6976
[3]   Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection [J].
Bonhoeffer, S ;
Rembiszewski, M ;
Ortiz, GM ;
Nixon, DF .
AIDS, 2000, 14 (15) :2313-2322
[4]   Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population [J].
Brown, AJL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (05) :1862-1865
[5]   HIV-1: Gambling on the evolution of drug resistance? [J].
Brown, AJL ;
Richman, DD .
NATURE MEDICINE, 1997, 3 (03) :268-271
[6]   Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection [J].
Cavert, W ;
Notermans, DW ;
Staskus, K ;
Wietgrefe, SW ;
Zupancic, M ;
Gebhard, K ;
Henry, K ;
Zhang, ZQ ;
Mills, R ;
McDade, H ;
Goudsmit, J ;
Danner, SA ;
Haase, AT .
SCIENCE, 1997, 276 (5314) :960-964
[7]   Quantification of latent tissue reservoirs and total body viral load in HIV-1 Infection [J].
Chun, TW ;
Carruth, L ;
Finzi, D ;
Shen, XF ;
DiGiuseppe, JA ;
Taylor, H ;
Hermankova, M ;
Chadwick, K ;
Margolick, J ;
Quinn, TC ;
Kuo, YH ;
Brookmeyer, R ;
Zeiger, MA ;
BarditchCrovo, P ;
Siliciano, RF .
NATURE, 1997, 387 (6629) :183-188
[8]   HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].
COFFIN, JM .
SCIENCE, 1995, 267 (5197) :483-489
[9]  
Devereux HL, 1999, AIDS, V13, pF123, DOI 10.1097/00002030-199912240-00001
[10]   Mutation takes no vacation: Can structured treatment interruptions increase the risk of drug-resistant HIV-1? [J].
Dorman, KS ;
Kaplan, AH ;
Lange, K ;
Sinsheimer, JS .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 25 (05) :398-402